Brn3a is a POU-domain transcription factor expressed in peripheral sensory neurons and in specific interneurons of the caudal CNS. Sensory expression of Brn3a is regulated by a specific upstream enhancer, the activity of which is greatly increased in Brn3a knockout mice, implying that Brn3a negatively regulates its own expression. Brn3a binds to highly conserved sites within this enhancer, and alteration of these sites abolishes Brn3a regulation of reporter transgenes. Furthermore, endogenous Brn3a expression levels in the sensory ganglia of Brn3a +/+ and Brn3a +/-mice are similar, demonstrating that autoregulation can compensate for the loss of one allele by increasing transcription of the remaining gene copy. Conversely, transgenic overexpression of Brn3a in the trigeminal ganglion suppresses the expression of the endogenous gene. These findings demonstrate that the Brn3a locus functions as a self-regulating unit to maintain a constant expression level of this key regulator of neural development.
Current density impedance imaging (CDII) is a new impedance imaging technique that can noninvasively measure the conductivity distribution inside a medium. It utilizes current density vector measurements which can be made using a magnetic resonance imager (MRI) (Scott , 1991). CDII is based on a simple mathematical expression for inverted Delta sigma / sigma = inverted Delta ln sigma, the gradient of the logarithm of the conductivity sigma, at each point in a region where two current density vectors J1 and J2 have been measured and J1 x J2 not equal 0. From the calculated inverted Delta ln sigma and a priori knowledge of the conductivity at the boundary, the logarithm of the conductivity ln sigma is integrated by two different methods to produce an image of the conductivity sigma in the region of interest. The CDII technique was tested on three different conductivity phantoms. Much emphasis has been placed on the experimental validation of CDII results against direct bench measurements by commercial LCR meters before and after CDII was performed.
Current density impedance imaging (CDII) is a new impedance imaging technique that utilizes current density vector measurements made using magnetic resonance imager (MRI). CDII provides a simple mathematical expression for the gradient of the logarithm of conductivity, nablaln(sigma), at each point in a region where two current density vector has been measured. From the images of the gradient of the logarithm of conductivity, ln(sigma) can be reconstructed through integration and of sigma by a priori knowledge of the conductivity at a single point in the object. The CDII technique was tested on a conductivity phantom made from tissue mimicking gel. The results showed accurate reconstruction of the gel conductivity from two current density measurements. This study, for the first time, has demonstrated a local reconstruction technique to calculate sample conductivity inside the phantom noninvasively.
Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.